TBC1D1 and neoplasm: Our mechanistic study revealed that TBC1D1-mediated inhibition of CTL function could be attributed to the upregulation of various immune checkpoint molecules, including ARG1, CD68, PDCD1, CD274, TGFB1, and CTLA4, collectively impeding the anti-tumor immune response (Figure 7C).